New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions

Join us for this dynamic, CME-certified symposium! Led by Steven M. Horwitz, MD, an expert panel will reveal how they approach current therapeutic decisions for their patients with PTCL and provide a look ahead at new data and promising agents that may soon change practice.

Sign up now! Registration is complimentary.

Friday Satellite Symposium preceding the 61st ASH Annual Meeting & Exposition.

Agenda

12:30 PM – 1:00 PM Lunch and Registration

1:00 PM – 1:10 PM Welcome and Introduction

1:10 PM – 2:00 PM PTCL Overview: Modern Molecular and Phenotypic Workup for PTCL

2:00 PM – 2:50 PM Case Discussions: Planning Frontline Treatment for Different PTCL Subtypes

2:50 PM – 3:40 PM Case Discussions: Improving Outcomes for R/R PTCL

3:40 PM – 4:00 PM Final Thoughts and Audience Question and Answer Session

Faculty

Program Chair
Steven M. Horwitz, MD

Associate Attending Physician
Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill-Cornell Medical Center
New York, New York

Faculty
Francine Foss, MD

Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Faculty
Barbara Pro, MD

Professor of Medical Oncology
Chief of Lymphoma Section
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Goal Statement
The goal of this activity is to improve participants’ competence and performance in integrating optimal therapy into the treatment of patients with PTCL.

Target Audience 
This program is intended for physicians and other healthcare providers who treat and manage patients with PTCL.

Learning Objectives

  • Understand how unique agent mechanisms of action can specifically target PTCL subtypes
  • Assess molecular and phenotypic biomarkers as part of the diagnosis of PTCL and individualization of therapy decisions
  • Plan frontline treatment strategies for PTCL based on available clinical data along with expert and guideline recommendations
  • Integrate available and promising therapeutic options in patients with relapsed/refractory PTCL
  • Refer eligible patients with PTCL to clinical trials of new agents and combination therapeutic strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.